Financials
Financial year 2025
Centre pharmaceutique de Louvain-la-Neuve from Ottignies-Louvain-la-Neuve, company number BE0412749054, closed financial year 2025 with a result of € 171,579 after tax. For that financial year Centre pharmaceutique de Louvain-la-Neuve recorded a gross margin of € 1.5 million and equity of € 2.4 million. Compared with financial year 2024, the result moved from € 126,563 to € 171,579. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 8, 2026.
€ 2.4 million
▲ 8% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 171,579
▲ 36% vs 2024
Profit after tax over the fiscal year.
€ 975,611
▲ 13% vs 2024
Cash and bank balances on the last day of the fiscal year.
People and assets in 2025
10.3
▼ 0.7 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 1.2 million
▲ 5% vs 2024
€ 113,000 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 838
▼ 88% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 555,828
▲ 16% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 116,910
▲ 7% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 1,150,098 | € 1,312,591 | € 1,392,252 | € 1,522,004 | ▲ 9% |
| Profit after taxes | € 59,484 | € 131,864 | € 126,563 | € 171,579 | ▲ 36% |
| Equity | € 2,019,748 | € 2,151,611 | € 2,278,174 | € 2,449,753 | ▲ 8% |
| Total debts | € 414,939 | € 574,986 | € 606,921 | € 675,223 | ▲ 11% |
| Cash | € 784,543 | € 747,037 | € 861,852 | € 975,611 | ▲ 13% |
| Land & buildings | € 255,929 | € 207,987 | € 164,366 | € 120,502 | ▼ 27% |
| Retained profit | € 2,019,748 | € 2,151,611 | € 2,278,174 | € 2,449,753 | ▲ 8% |
| Balance sheet total | € 2,434,687 | € 2,726,597 | € 2,885,095 | € 3,124,976 | ▲ 8% |
| Employees (FTE) | 11 | - | 11 | 10.3 | ▼ 0.7 |
Key figures of Centre pharmaceutique de Louvain-la-Neuve, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Centre pharmaceutique de Louvain-la-Neuve?
What happened at Centre pharmaceutique de Louvain-la-Neuve in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 171,579 (▲ 36% vs 2024). Source: NBB ↗
- New establishment in Ottignies-Louvain-la-Neuve. KBO
- New establishment in Sint-Lambrechts-Woluwe. KBO
- New establishment in Ottignies-Louvain-la-Neuve. KBO
- Start of the company according to the CBE. KBO
In short
From € 59,484 profit in 2022 to € 171,579 profit in 2025.
Paid € 70,076 in corporate taxes since 2022.
Best year ever: 2025, with € 171,579 profit.
On average € 147,800 of value added per employee in 2025.
A new publication or filing at Centre pharmaceutique de Louvain-la-Neuve? We notify you, reason included.
Follow Centre pharmaceutique de Louvain-la-NeuveDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind Centre pharmaceutique de Louvain-la-Neuve are JOELLE LECLERCQ, EMMANUEL HERMANS, Françoise VAN BAMBEKE, Francis VAN DER MAREN, Benoit MOUSSET and Pierre VOSSEN. Francis VAN DER MAREN is also behind Les Jacinthes and Madras Bruxelles.
Directors
According to the 2025 annual accounts
JOELLE LECLERCQ
Director
EMMANUEL HERMANS
Director
Françoise VAN BAMBEKE
Director
Benoit MOUSSET
Director
Pierre VOSSEN
Director
Also active at: Foltadel, Westlimco, MEDICAL WEB SERVICES, MEDIPIM, BELINCO, EXOS KVK, Noé Nature, INVESTA QUETELET +1 more
LEON WILMOTTE
Director
Yves HORSMANS
Director
Dominique WOUTERS
Director
Establishments
Establishment units
Physical locations of this company
Traverse d'Esope 5-7
1348 Ottignies-Louvain-la-Neuve
Hippokrateslaan 10
1200 Sint-Lambrechts-Woluwe
Active since 2 May 2016
Place de l'Equerre 31
1348 Ottignies-Louvain-la-Neuve
Active since 1 December 2020
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0412.749.054
- VAT number
- BE 0412.749.054
- Registered office
- Traverse d'Esope 5-7, 1348 Ottignies-Louvain-la-Neuve
- Names & denominations
- Centre pharmaceutique de Louvain-la-Neuve
- Enterprise type
- Rechtspersoon
- Legal form
- Non-profit association
- Legal situation
- Normale toestand
- Start date
- 15 November 1972
- Peppol
- Active · Active since 26 Jan 2026
- Activities · NACE
Detailhandel in farmaceutische producten
Apothekers